Online Program Home
My Program

CC = Colorado Convention Center   H = Hyatt Regency Denver at Colorado Convention Center
* = applied session       ! = JSM meeting theme

Activity Details

172 Mon, 7/29/2019, 10:30 AM - 12:20 PM CC-109
Quantitative Decision Making in Clinical Trials — Contributed Papers
Biopharmaceutical Section
Chair(s): Xiao Fang, Merck
10:35 AM Defensive Efficacy Interim Design: Dynamic Benefit/Risk Ratio View Using Probability of Success
Zhongwen Tang, Abbvie
10:50 AM In Silico Clinical Trials : a Way to Improve Clinical Development?

Nicolas SAVY, Toulouse Institute of Mathematics; Philippe SAINT-PIERRE, Toulouse Institute of Mathematics ; Stephanie SAVY, ESTRIALS; Emmanuel PHAM, IPSEN Innovation SAS
11:05 AM Single-Arm Two- and Three-Stage Phase 2 Clinical Trials with Go/No-Go/Inconclusive Outcomes with Handling of Overrunning/Under-Running

Bob Zhong, Johnson and Johnson; Wenchuan Guo, Bristol-Myers Squibb Company; Jianan Hui, Boehringer Ingelheim Pharmaceuticals Inc.
11:20 AM Quantitative Decision-Making for Single Arm POC Studies in Early Phase Oncology
Zhuqing Tina Liu, Eli Lilly and Company; Jingyi Liu, Eli Lilly and Company
11:35 AM Quantitative Decision Making in Early Clinical Development – Some Statistical Considerations
Weidong Zhang, Pfizer
11:50 AM Bayesian Interim Prediction of Probability of Clinical Trial Success
Ying Grace Li, Eli Lilly and Company
12:05 PM Infusing Bayesian Strategies for Pharmaceutical Manufacturing and Development

Bill Pikounis, Johnson & Johnson; Dwaine Banton, Janssen R&D; John Oleynick, Johnson & Johnson; Jyh-Ming Shoung, Janssen R&D